Bayer Builds On Oncology Pipeline With Nycomed’s Divested Kinase Inhibitors
This article was originally published in The Pink Sheet Daily
Executive Summary
Acquisition of two candidates and back-up compounds complements ongoing Nexavar efforts, Bayer says.